Poor
Mostly Aligned
Patient Risk:
Low
Summary
Only two claims about product identity/active ingredient and general FDA approval context are supported by the provided label excerpts; multiple claims about pricing and bulk ordering are not supported by FDA-approved prescribing information, materially reducing label alignment.
Category Scores
Accurate Statements
Vascepa is a prescription medication containing icosapent ethyl.
Supported by label: 11 DESCRIPTION (icosapent ethyl in VASCEPA capsules).
Vascepa is approved by the FDA for the treatment of high triglycerides.
Supported by label: 1 INDICATIONS AND USAGE (adjuncts to statin therapy to reduce risk in adults with elevated TG; adjunct to diet to reduce TG in severe hypertriglyceridemia).
Vascepa has been shown to reduce the risk of cardiovascular events in patients with established cardiovascular disease.
Partially supported by label: 1 INDICATIONS AND USAGE and 14.1 Prevention of Cardiovascular Events (risk reduction shown in a trial population that included patients with established cardiovascular disease; however the claim does not reflect the label’s more specific adjunct/eligibility criteria).
Unsupported Statements
The average retail price of Vascepa 1 g capsules is around $150 per 30-day supply.
No pricing information is provided in the supplied label excerpts; retail pricing claims are not supported by prescribing information.
Prices of Vascepa can range from $100 to over $300 per 30-day supply depending on the pharmacy and location.
Retail price ranges are not contained in the supplied label excerpts; not supported by prescribing information.
Bulk orders of Vascepa can provide cost savings for patients who require long-term treatment.
No bulk ordering or cost-savings statements are present in the supplied label excerpts.
Bulk orders can take advantage of discounts and rebates offered by manufacturers and pharmacies.
Discount/rebate or manufacturer/pharmacy billing arrangements are not described in the supplied label excerpts.
Bulk orders can simplify the process of refilling prescriptions by requiring ordering a single shipment rather than multiple smaller quantities.
Operational/refill logistics are not described in the supplied label excerpts.
Bulk orders can reduce the administrative burden on patients and healthcare providers by resulting in fewer prescriptions needing to be filled and managed.
Administrative process claims are not described in the supplied label excerpts.
A study in the Journal of Clinical Lipidology found that patients who ordered Vascepa in bulk saved an average of 25% compared to those who purchased the medication in smaller quantities.
No such external study, setting (bulk ordering), comparator, or numeric savings is described in the supplied label excerpts.
The study in the Journal of Clinical Lipidology found that bulk ordering reduced the administrative burden on patients and healthcare providers.
No such external study or administrative-burden findings are described in the supplied label excerpts.
Patients can contact Amarin Pharmaceuticals to inquire about bulk ordering options and pricing.
No contact instructions or bulk ordering/purchasing guidance is provided in the supplied label excerpts.
Specialty pharmacies may offer bulk ordering options and discounts.
No information about specialty pharmacy bulk ordering/discounts is provided in the supplied label excerpts.
Patients can order Vascepa in bulk online through specialty pharmacies or the manufacturer's website.
No online bulk ordering pathways or purchasing instructions are provided in the supplied label excerpts.
Contradictions
Important Omissions
No label-aligned safety/usage context is provided (e.g., contraindications, warnings/precautions, dosing/administration, and key limitations of use).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The provided claims are predominantly non-label commercial information (pricing/bulk ordering) rather than incorrect dosing or explicit safety misstatements; however, omission of label-required safety and dosing context contributes to overall label non-adherence.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Major portion of claims (pricing and bulk ordering/logistics/discounts) is not supported by FDA-approved prescribing information provided.
Suggested Improvement
Remove or replace all non-label commercial/pricing/bulk ordering claims with label-supported information (indications, dosing/administration, safety/contraindications, warnings/precautions, and limitations of use).